News
Milestone Pharmaceuticals Appoints Paul Truex to the Board of Directors
Pharmacy Choice
March 5, 2012
Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study
December 1, 2011
Anthera Pharmaceuticals, Inc. (ANTH) Announces Last Patient Enrolled in PEARL-SC Study
BioSpace
October 26, 2011
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
BioPortfolio - Original Article
June 16, 2011
Anthera Pharmaceuticals announces pricing of $31.5 million PIPE financing
Download the PDF
September 21, 2010
Anthera Pharmaceuticals
San Mateo, CA
Nasdaq: ANTH
Anthera Pharmaceuticals is a pharmaceutical development company focused on the advancement of promising clinical products for the treatment of serious inflammatory diseases. Anthera's lead products are inhibitors of secretory phospholipase A2. The lead product is in Phase 3 development for acute coronary syndrome and a second program is in Phase 2b trials to treat patients with lupus.